ASHA-624
Pre-clinical- Indications
- Amyotrophic Lateral Sclerosis
Company intelligence / Profile preview
Asha Therapeutics
Washington, District of Columbia, United Statesashatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Asha Therapeutics has nominated two lead candidates—ASHA‑624 targeting SARM1 for ALS and related neuropathies, and ASHA‑091 for Alzheimer’s, Parkinson’s, and ALS. Both have shown robust efficacy in preclinical models. The company expects to initiate first-in-human clinical trials by late 2024 or early 2025. No active clinical trials are currently registered on ClinicalTrials.gov as of May 2025.
- Therapeutic areas
- OphthalmologyOncologyNeurologyInfectious Diseases
- Modalities
- Small molecules (including "intra-molecular glue" inhibitors)De novo designed chemical entities via PRISM™ platform
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Johnson & Johnson Innovation – JLABS/BARDA through the BLUE KNIGHT™ program partnership for rapid response drug development initiatives.
Beyond the preview
Go deeper on Asha Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asha Therapeutics.